Otsuka’s Lupkynis receives NICE green light
Recommendation applies across England and Wales and the treatment is available now
Read More
Tag: otsuka
Otsuka receives vital Lupkynis MHRA authorisation
Therapy represents first oral calcineurin-inhibitor treatment for active lupus nephritis in adults
Read More
PhoreMost enlists Otsuka in multi-project drug discovery collab
The partnership will have an initial focus on gene therapy applications of identified targets.
Read More
MSD enlists Otsuka units Taiho and Astex to develop KRAS therapies
KRAS therapies had their break-out moment in 2019, with Amgen’s KRAS inhibitor becoming the first drug of its type to post clinical data last September, demonstrating that it shrank tumors in 90% of lung cancer patients.
Read More
Rexulti falls short of goal in late-stage bipolar disorder studies
Lundbeck’s Rexulti has failed to achieve the primary endpoint of two Phase III bipolar disorder studies.
Read More
GW regains US rights to Sativex
GW Pharmaceuticals has reacquired full ownership of US rights to its cannabinoid medicine Sativex following the termination of a previous license agreement with Otsuka.
Read More
Cambridge Uni launches new industry/academia initiative
A new initiative that aims to establish a “world-leading platform” for collaboration between academia and industry in the development of therapeutics is being launched by the vice-chancellor of the University of Cambridge.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
